Abbott Laboratories (NYSE:ABT) Price Target Raised to $157.00

Abbott Laboratories (NYSE:ABT) had its price target raised by The Goldman Sachs Group from $153.00 to $157.00 in a research note released on Wednesday,MarketScreener reports. They currently have a buy rating on the healthcare product maker’s stock.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company dropped their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research report on Friday, July 18th. Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Mizuho boosted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Evercore ISI boosted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Finally, Royal Bank Of Canada upped their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $145.39.

Abbott Laboratories Stock Up 1.1%

Abbott Laboratories stock opened at $134.49 on Wednesday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a market capitalization of $234.07 billion, a P/E ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.69. The stock has a 50-day simple moving average of $131.94 and a 200-day simple moving average of $131.33.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the previous year, the business earned $1.14 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Iowa State Bank raised its position in Abbott Laboratories by 0.6% in the third quarter. Iowa State Bank now owns 14,742 shares of the healthcare product maker’s stock valued at $1,975,000 after purchasing an additional 85 shares during the period. Summit Financial Wealth Advisors LLC raised its position in Abbott Laboratories by 11.8% in the third quarter. Summit Financial Wealth Advisors LLC now owns 2,387 shares of the healthcare product maker’s stock valued at $319,000 after purchasing an additional 251 shares during the period. Aaron Wealth Advisors LLC raised its position in Abbott Laboratories by 49.9% in the third quarter. Aaron Wealth Advisors LLC now owns 22,067 shares of the healthcare product maker’s stock valued at $2,956,000 after purchasing an additional 7,348 shares during the period. Shorepoint Capital Partners LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $725,000. Finally, GAMMA Investing LLC increased its position in shares of Abbott Laboratories by 3.3% during the third quarter. GAMMA Investing LLC now owns 47,146 shares of the healthcare product maker’s stock worth $6,315,000 after acquiring an additional 1,499 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.